Lexeo Therapeutics (NASDAQ:LXEO) Announces Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Lexeo Therapeutics (NASDAQ:LXEO) released its quarterly earnings results on Monday. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09, Zacks reports.

Lexeo Therapeutics Price Performance

Shares of NASDAQ LXEO traded up $1.38 during midday trading on Monday, reaching $4.09. The company’s stock had a trading volume of 6,910,396 shares, compared to its average volume of 328,570. The company has a market cap of $135.24 million, a price-to-earnings ratio of -1.29 and a beta of 3.85. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $4.19 and a 200 day moving average price of $6.76. Lexeo Therapeutics has a one year low of $2.32 and a one year high of $19.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on LXEO shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 21st. Leerink Partners dropped their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $23.60.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.